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We investigated clinical and cellular phenotypes of 24 children with mutations in the catalytic (alpha) subunit
of the mitochondrial DNA (mtDNA) gamma polymerase (POLG1). Twenty-one had Alpers syndrome, the com-
monest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA
depletion. The cellular mtDNA content reﬂected the genotype more closely than did clinical features. Patients
with tissue depletion of mtDNA all had at least one allele with either a missense mutation in a catalytic domain
or a nonsense mutation. Four out of 12 patients exhibited a progressive, mosaic pattern of mtDNA depletion
in cultured ﬁbroblasts. All these patients had mutations in a catalytic domain in both POLG1 alleles, in either
the polymerase or exonuclease domain or both. The tissue mtDNA content of patients who had two linker
mutations was normal, and their phenotypes the mildest. Epilepsy and/or movement disorder were major fea-
tures in all 21. Previous studies have implicated replication stalling as a mechanism for mtDNA depletion. The
mosaic cellular depletion that we have demonstrated in cell cultures may be a manifestation of severe repli-
cation stalling. One patient with a severe cellular and clinical phenotype was a compound heterozygote with
POLG1 mutations in the polymerase and exonuclease domain intrans. This suggests that POLG1 requires
both polymerase and 30–50 exonuclease activity in the same molecule. This is consistent with current func-
tional models for eukaryotic DNA polymerases, which alternate between polymerizing and editing modes, as
determined by competition between these two active sites for the 30 end of the DNA.
INTRODUCTION
First described in 1991, mtDNA depletion is the central
feature of a group of disorders, collectively termed mtDNA
depletion syndromes (MDS) (1,2). The characteristic
mtDNA ﬁnding in these disorders is a quantitative reduction
in the mtDNA content of affected tissues, but there may also
be low levels of heteroplasmy for point mutations (3).
Defects in mtDNA maintenance have been hard to study as
the mtDNA defects are only evident in primary ﬁbroblast
cultures (4) from a minority of patients and are rarely
described in other primary lines (5). Unlike mtDNA
mutations, the pattern of inheritance of MDS is autosomal
recessive. Furthermore, mtDNA content and OXPHOS
activity was restored in cybrids generated from the fusion of
mtDNA-free (r8) cells with enucleated ﬁbroblasts from
MDS patients (6), implying an underlying nuclear defect.
Previous investigators have classiﬁed MDS into two main
groups, consisting of a hepatocerebral form and a myopathic
form (7,8). In both groups several tissues may be affected
(9). Genes involved in the hepatocerebral form include
POLG1 (10), deoxyguanosine kinase (dGK) (11), the human
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mitochondrial helicase/primase, TWINKLE (13) and the
alpha subunit of Succinyl-CoA Synthase (SUCLG1) (14).
MDS without hepatic involvement is associated with myopa-
thy and/or encephalopathy. Mutations have been identiﬁed in
genes encoding the mitochondrial thymidine kinase (TK2)
(11), the beta subunit of ADP-Forming Succinyl-CoA Synthase
(SUCLA2) (15), the P53 dependent subunit of ribonucleotide
reductase (RRM2B) (16) and thymidine phosphorylase (or
TP, associated with MyoNeuroGastroIntestinal Encephalomyo-
pathy or MNGIE) (17). Myopathic MDS may present as the
so-called ‘benign’ later-onset mtDNA depletion (18).
By far the commonest gene defects identiﬁed in autosomal
recessive mtDNA depletion are POLG1 mutations. POLG1 is
the gene encoding the 195 kDa catalytic (alpha) subunit of the
mitochondrial (gamma) DNA polymerase, located on chromo-
some 15q25. Three polymerase domains (exons 17–22) are
separated from 3 exonuclease domains (exons 2–8) by a
linker region (residues 418–755) that interacts with the beta
subunit. Mutations in POLG1 are associated with a range of
different phenotypes (19). These include both dominant and
recessive chronic progressive ophthalmoplegia, mitochondrial
recessive ataxia syndrome (20) and recessive, severe, early
onset Alpers syndrome (10). While some authors distinguish
between Alpers syndrome, characterized by refractory sei-
zures, deafness, cortical blindness, episodic psychomotor
regression, and Alpers–Huttenlocher syndrome in which
liver disease is also a major feature (21), such a subdivision
requires detailed data. Alpers syndrome is marked by a pro-
gressive deterioration, most patients dying in infancy but a
few surviving into their teens (22). POLG1 genotype:pheno-
type correlations in both Alpers and mtDNA depletion have
been disappointing (19). We sought to develop these using
accurate quantitation of tissue mtDNA content and cellular
depletion phenotype.
RESULTS
We investigated 24 children in whom we had identiﬁed POLG
gene mutation(s). These patients were referred with childhood
onset of symptoms that were suggestive of POLG1 mutations,
such as Alpers syndrome, or because we had previously ident-
iﬁed mtDNA depletion or multiple DNA deletions. Features of
the 24 patients with POLG1 mutations are summarized in
Table 1. Age ranged from 0 to 17 years and 9/10 patients
with mtDNA depletion in liver or muscle were male.
Genotype–phenotype correlation
Sequence analysis of the POLG1 gene revealed two mutant
alleles in all of the patients with Alpers disease consistent
with recessive inheritance. Three individuals had a largely
neurological presentation that clearly fell outside the accepted
criteria for Alpers disease, but the remainder all had encepha-
lopathy. Seventeen out of the remaining 23 (74%) had a vari-
able degree of liver dysfunction, from mild to liver failure
requiring transplant. Of the 20 out of 21 individuals with prob-
able Alpers syndrome where clinical information was avail-
able, all had epilepsy, which was intractable (epilepsia
partialis continua) in four. One teenage patient died only 2
years after presentation, ending with 5 months of continuous
seizure activity. Epilepsy was treated with sodium valproate
in four out of the 11 where we had information about anticon-
vulsant therapy, and in one case this was followed by deterio-
ration and death within 3 months. Movement disorders
(choreoathetosis, ataxia and ataxic nystagmus) and epilepsia
partialias continua were common features. None of the
patients had survived to their 19th birthday, the median age
at death being 1 year (7 months to 18 years).
The mtDNA content of liver was low in all cases where it
was available, but was variable in muscle (22–117%). All
of the patients with mtDNA depletion in liver and/or muscle
had at least one missense or nonsense mutation in a catalytic
domain, either at least one mutation in the polymerase
domain or two mutations in the exonuclease domain.
Fibroblast nucleoid mtDNA distribution deﬁnes a
distinctive subgroup of patients with mosaic cellular
depletion that is reﬂected by low mtDNA content of tissue
and poor life expectancy
Fibroblast cultures were available for 10/24 of the patients for
visualizing mtDNA using PicoGreen ﬂuorescence microscopy.
PicoGreen can quantitatively stain mtDNA (23), which in vivo
is arranged into punctate DNA/protein structures termed
nucleoids, which consist of several mtDNA genomes com-
plexed to nucleoid proteins like POLG. In normal control
cells, PicoGreen stains numerous nucleoids that are of com-
parable ﬂuorescence intensity in different cells and between
different individuals. However, some of the patient ﬁbroblast
cultures, such as that from patient A (Fig. 1) showed mosaic
depletion, in that many cells showed greatly reduced nucleoid
staining, suggesting mtDNA depletion, which was most
noticeable at later cell passages (approximately 2–3 months
continuous culture). This was evident in cultured cells
derived from four individuals (patients A–D Fig. 1 and
Table 1). In all cases nuclear staining was unaffected, although
cytoplasmic background ﬂuorescence was often increased.
These patients with mosaic depletion within their cultured
ﬁbroblasts all had severe clinical phenotypes, all being dead
by the age of 16 months. Of these, patient A had much the
highest proportion of depleted cells, and this was probably a
later passage than cultures B–D. The mosaic distribution of
mtDNA depletion was also apparent at low cell passage
number (Supplementary Material, Fig. S1), where occasional
mtDNA-free (rho zero) cells were present (Supplementary
Material, Fig. S1), interspersed with cells with apparently
normal or near normal mtDNA levels. Cultures A–C were
grown until at least passage 20, and the proportion of depleted
cells increased with successive passage (compare Fig. 1 with
Supplementary Material, Fig. S1), so that by 45 days the
majority of cells were depleted (Fig. 2A). This was reﬂected
by a reduced minimum ﬁbroblast mtDNA content by Q-PCR
(Table 1) in cells from patients A–D (average 23%), but at
baseline patient D had infrequent depleted cells and much
higher mtDNA content (97%, relative to control ﬁbroblast
cultures 39–193%). There was no consistent change in
mtDNA content in any of the ﬁbroblast cultures from controls
(Fig. 2), from patients with other types of mitochondrial
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Identiﬁer Sex Mutation Mutation Cellular Age mtDNA content (%) Epilepsy Hepatopathy Movement disorder
(Ref.) Location Depletion? Onset Liver Muscle Fibroblasts Valproate
A (22,27) M T914PþR1096C PþP Yes ,1 year 7 23 19–27 þþ (þ)
B M H277Cþ T851A PþE Yes 6 months 4 32 36–60 þþ
C M R1096C homozygous PþP Yes 5 months 16–55 þþ
D (38) F R232Gþ[T251I;P587L] Eþ[EL] Yes 5 months 4 22–97 þþ
E (29) M R627WþT914P PþL Borderline Birth 5 54 30–77 2 þþ þ
F M W748Sþ[R852C;G11D] PþL No 1 year 32 38 þþ þ (þ)
G M A467Tþ[R852C;G11D] PþL No 2 years 3 months 22 37 2 þþ 2
H F A467TþT914P PþL No 7 months 39 62 þþ þ
I M W748SþT914P PþL No 4 years 15 84 þþ þ þ
J (21,27) M E873Xþ A467T LþX Borderline 18 months 25 30 51 þþ þ
K M A467TþW347_L365del EþL Unknown 7 months 2 þþ (þ)
L F W748SþW748S LþL Unknown 16 years 108 þþ (þ)( þ)
M F L304R homozyg EþE Unknown 10 year 117 22 2 2
N M W748SþT914P PþL Unknown 13 months 43 þþ þ
O F W748SþG848S PþL Unknown 6 years 222 þ 2 þ
P F A467TþT914P PþL Unknown 15 years 222 þ
Q F A467TþG848S PþL Unknown 18 months 2 þ (þ) 2
R F A467TþL966R PþL Unknown 4 years þ 2
S F A467TþR374X LþX Unknown 4 months 2 þþ (þ)
T M A467TþR417T EþL Unknown 2 years 222 2
U M H569Q homozygous LþL Unknown 15 years 78 22
V M W748Sþ[P587L,P589L] LþL Unknown 17 years 222 þ 2
W F A467TþA467T LþL Unknown 16 years 222 þþ
X F A467TþC418R LþL Unknown 3 years þ 2 þ
Mean (%) 13.1 54.6
Controls 40–152 60–140 39–193
P, mutation in polymerase domain; PþP, two mutations in polymerase domain; L, Linker domain; E, exonuclease domain; X, nonsense mutation.
Blanks denote unknown; þ, present; (þ); present but not prominent; 2, absent.
Fibroblast mtDNA content were measured on several occasions on the lines containing rho zero cells, range shown.
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6disease or from POLG1 patients who were not mosaic for
depleted cells (patients G–J). However, in two cell cultures
(E and F), occasional depleted cells were apparent (24,25),
particularly as the cultures became senescent, but this was
not a consistent, progressive feature. Thus the mosaic cellular
distribution of mtDNA in ﬁbroblast cultures A–D was charac-
teristic, differing from all other ﬁbroblasts examined and
marking them out as a distinctive subgroup.
The mtDNA content of liver was marginally lower in the
mosaic patients A–D (average 5%, range 4–7%) than the
other patients (average 19%, range 5–32%), but this was not
signiﬁcant (P ¼ 0.09). Muscle mtDNA content was also some-
what reduced (average 27%, range 22–32%) but this was not
signiﬁcantly less than the rest of the patients. Muscle mtDNA
was normal in the patients with only linker mutations (26),
mtDNA content being signiﬁcantly higher in these than the
other patients (average 93 and 34% respectively, P ¼ 0.001)
with earlier onset Alpers disease (average age 16 and 1 year,
respectively, P , 0.001).
Characteristics of the cellular mtDNA depletion identiﬁed
in patients A–C
The reduction in mtDNA content was assessed by quantitative
analysis of digital images, which showed that while the
number of nucleoids detectable by PicoGreen signiﬁcantly
declined with time (Fig. 2B, P , 0.001 and ,0.01 for early
and late time points for patients B and C, respectively), the
distribution of their intensities barely changing (Fig. 2C).
That is, nucleoid numbers were reduced (Fig. 2B) but no
less intense (Fig. 2C) in depleted cells in the mosaic patients.
We further studied the mosaic mtDNA depletion in cultured
cells from patients A–C, using a battery of in situ approaches.
Immuno-ﬂuorescence with antibodies against anti-DNA,
which detect mtDNA nucleoids as small cytoplasmic dots con-
ﬁrmed the presence of numerous cells within cultures A–C
with mosaic and severe mtDNA depletion, which were not
observed in any of the controls (Fig. 3A, top panels). Mito-
tracker co-labelling indicated many of these depleted cells
also exhibited reduced Mitotracker labelling. As Mitotracker
speciﬁcally labels mitochondria according to their membrane
potential, a reduced Mitotracker labelling indicates these
mtDNA depleted cells also manifested reduced membrane
potential. Similar results were observed with anti-bodies to
mitochondrial transcription factor A (TFAM), a nucleoid
protein reduced by loss of mtDNA, which showed that numer-
ous cells within cultures A–C exhibited reduced TFAM
expression (Fig. 3Af–h), unlike the homogenous labelling of
controls (Fig. 3Ae and Supplementary Material, Fig. S1A).
Mitotracker co-labelling showed many of the TFAM reduced
cells also contained reduced Mitotracker labelling. Interest-
ingly, some mitochondria within anti-DNA/TFAM depleted
cells retained Mitotracker labelling, and these invariably
co-localized with residual anti-DNA/TFAM expression
(arrowed, Fig. 3Ad and Supplementary Material, Fig. S1).
Bromodeoxyurudine (BrdU) labelling of newly synthesized
DNA within cultures A–C (Fig. 3Aj–l) showed markedly
reduced mtDNA replication compared with controls
(Fig. 3Ai), with fewer nucleoids incorporating BrdU and a
weaker nucleoid labelling. Nuclear BrdU labelling was unaf-
fected. Again, cells with profoundly reduced BrdU also
often showed markedly reduced Mitotracker signals (data
not shown). A number of patient cells showed a near
absence of mtDNA replication (see asterisks in Fig. 3Ak
and l).
We next examined the cellular expression of the mtDNA
encoded cytochrome c oxidase subunit I (COXI, Fig. 3B).
COXI immunolabelling showed mosaic COXI expression in
cultures A–C, with numerous cells exhibiting reduced
COXI, unlike the homogenous expression of controls
(Fig. 3Ba–d). Global COXI expression was reduced in
cultures A and B (data not shown). COXI reduced cells
again often showed substantially reduced Mitotracker label-
ling, although individual polarized mitochondria often
Figure 1. PicoGreen staining reveals marked mtDNA depletion in certain MDS patient derived ﬁbroblast cell cultures, that alters with cell passage (A) Pico-
Green staining of a later passage of patient A’s cells showed a very weak nucleoid staining, and nucleoids were barely visible in most cells. (B) PicoGreen
staining of a later passage of patient B’s ﬁbroblasts also revealed a similar decline in nucleoid staining, compared with earlier passages. (C) PicoGreen staining
of later passage patient C’s ﬁbroblasts. (D) Patient D showed occasional depleted ﬁbroblasts. (E) There was little difference in PicoGreen staining of early
passage (p4) ﬁbroblasts and (F) late passage ﬁbroblasts (p25) derived from healthy control. Insets show magniﬁed areas of interest. Bars 20 mm.
Human Molecular Genetics, 2008, Vol. 17, No. 16 2499co-localized with residual COXI expression (arrowed, Sup-
plementary Material, Fig. S3B). A reduced cytochrome c
oxidase (COX) relative to nuclear encoded succinate dehydro-
genase (SDH) activity was detected in many cells within cul-
tures A–C (Fig. 3Be–l).
Finally, to conﬁrm that TFAM, anti-DNA, COXI, BrdU
reduced cells within cultures A–D correlated to the PicoGreen
reduced cells, we co-labelled these cells with PicoGreen
and tetramethyl-rhodamine-methyl ester (TMRM), a dye
similar to Mitotracker in that it is absorbed into mitochondria
according to mitochondrial membrane potential (Fig. 3C).
Many PicoGreen depleted cells were found to have depolar-
ized mitochondria (Fig. 3C, arrowed).
DISCUSSION
We have found that mtDNA depletion of tissues and cultured
ﬁbroblasts from patients with POLG1 mutations is associated
particularly with mutations in catalytic domains. We have
identiﬁed mosaic mtDNA depletion of mtDNA in primary
Figure 2. (A) Quantiﬁcation of PicoGreen staining of proportion of mosaic MDS cell cultures A–C that appeared depleted over time. The number of cells that
appeared depleted of mtDNA increased over 45 days in the patients but not the controls (200 cells were counted at each time point). Numbers were signiﬁcantly
higher in patients than controls at all time points, other than 28 days (0.05,P , 0.0016). (B) Quantiﬁcation of the numbers of nucleoids visible by PicoGreen
staining of mosaic MDS cell cultures A–C and controls [same experiment as (C) and Supplementary Material, Fig. S2]. Nucleoid numbers drop with time in
MDS cultures (P , 0.001 and ,0.01 for early and late time points for patients B and C, respectively). In all three patients the number of nucleoids at the late
time points are signiﬁcantly fewer than controls (P , 0.0002). (C) Quantiﬁcation of the intensity of PicoGreen staining of indiviual nucleoids from mosaic MDS
cells [same experiment as (B) and Supplementary Material, Fig. S2]. The distribution of nucleoid intensities is similar in patients (early and late passage) and
controls (only patient B is shown, whose nucleoid numbers showed the most signiﬁcant drop).
2500 Human Molecular Genetics, 2008, Vol. 17, No. 16Figure 3. (A) MDS cells are mosaic for expression of mtDNA and mitochondrial transcription factor A (TFAM) and have reduced mtDNA synthesis compared
with controls. (a) Control ﬁbroblasts co-labelled with anti-DNA antibody (green) and Mitotracker red, showing orange-yellow labelling were there two signals
co-localize. (b) Patient A ﬁbroblasts co-labelled with anti-DNA/Mitotracker. (DAPI was used to visualize nuclei blue and an asterisk denotes a cell with no
anti-DNA signal). (c) Patient B ﬁbroblasts co-labelled with anti-DNA/Mitotracker. (note: a reduced anti-DNA signal is shown by the predominantly red
co-localization with Mitotracker). (d) Patient C ﬁbroblasts co-labelled with anti-DNA/Mitotracker (arrow shows area of residual anti-DNA/mitotracker
co-labelling within a depleted cell with reduced Mitotracker labelling). (e) Control ﬁbroblasts co-labelled with anti-TFAM antibody (green) and Mitotracker
red. (f) Patient A ﬁbroblasts co-labelled with anti-TFAM/Mitotracker (asterisks show TFAM depleted cells with reduced Mitotracker labelling). (g) Patient
B ﬁbroblasts co-labelled with anti-TFAM/Mitotracker. (h) Patient C ﬁbroblasts co-labelled with anti-TFAM/Mitotracker. (i–l) Fibroblasts pulsed with Bromo-
deoxyuridine (BrdU) for 220 min, and Br-DNA immuno-detected. (i) BrdU labelling of normal ﬁbroblasts, (j) BrdU labelling of patient A cells (inset shows
magniﬁed area of cytoplasm showing weak BrdU labelling). (k) BrdU labelling of patient B cells. (l) BrdU labelling of patient C cells (note: asterisks mark
‘r8 type’ cells with very little or no mtDNA labelling). Bar 20 mM. (B) Expression of mtDNA encoded cytochrome c oxidase subunit I (COXI) in MDS patients
is reduced, as is COX activity, but not SDH activity. Cytochrome c oxidase subunit I (COXI) expression was monitored using immuno-cytochemistry. (a) COXI
labelling of normal control ﬁbroblasts. (b) COXI labelling of patient A ﬁbroblasts (COXI depleted cells are asterisked). (c) COXI labelling of patient B ﬁbro-
blasts. (d) COXI labelling of patient C ﬁbroblasts. (e–h) Histochemical demonstration of in situ COX activity in ﬁbroblasts. (e) COX activity of control. (f) COX
activity of patient A cells (asterisks denote cells with markedly reduced activity). (g) COX activity of patient B cells. (h) COX activity of patient C cells. (i–l)
Histochemical demonstration of in situSDH activity in ﬁbroblasts. (i) SDH activity of control cells. (j) SDH activity of patient A cells. (k) SDH activity of patient
B cells. (l) SDH activity of patient C cells. Bars 20 mM. (C) Tetramethyl-rhodamine-methyl ester (TMRM)/PicoGreen co-labelling of mosaic MDS ﬁbroblast
mitochondrial membrane potential. (a) PicoGreen labelling of normal control ﬁbroblasts. (b) Co-staining of the same cells with TMRM. (c) Co-localization of the
two signals in (a) and (b). (d and e) PicoGreen/TMRM co-labelling of later passage Patient A’s ﬁbroblasts. (f) Co-localization of the two signals in (d) and (e). (g
and h) PicoGreen/TMRM co-labelling of later passage Patient B’s ﬁbroblasts. (i) Co-localization of the two signals. (j and k) PicoGreen/TMRM co-staining of
late passage Patient C’s cells. (l) Co-localization of the two signals. (m and n) PicoGreen/TMRM co-staining of late passage Patient D’s cells. (o) Co-localization
of the two signals. Bars 20 mm.
Human Molecular Genetics, 2008, Vol. 17, No. 16 2501ﬁbroblast cultures from some patients with Alpers disease. In
patients A–C, mtDNA was depleted in cells with reduced
COX activity. These cells also had reduced mitochondrial
membrane potential, suggesting that the depletion and not
the point mutations underlie the major part of the respiratory
chain defect in ﬁbroblasts from these POLG1 patients (Sup-
plementary Material, Fig. S4). In all cases, cellular mosaic
depletion was associated with two mutations in catalytic
regions of POLG1, either in the polymerase or exonuclease
domain or in one of each. The mtDNA depletion manifested
primarily as a reduced number of nucleoids in the depleted
cells and reﬂected the severity of the clinical and tissue pheno-
types. The cellular mtDNA content may be an indicator of
the underlying molecular mechanism that links genotype to
phenotype. These data from a human disease suggest that
eukaryotic DNA polymerases require both polymerase and
30–50exonuclease activities within the same molecule.
Previous studies of human POLG1 mutations have found
little in the way of clear genotype–phenotype correlations,
and these may have been more apparent in the present study
as it has been possible to link a range of clinical phenotypes
with laboratory data that included both tissue mtDNA
content and cellular phenotypes. Our clinical ﬁndings were
similar to previous studies, conﬁrming that epilepsy and
movement disorders (27) are major features of POLG1 syn-
dromes. Relatively complete information was available for
the four patients who manifested mosaic mtDNA depletion,
whereas the clinical data available on the other patients was
largely retrospective, hence dependent on the local neurol-
ogist. We found that the cellular phenotype correlated better
with the location of the mutation and the severity of the
tissue depletion than with speciﬁc clinical features. Neverthe-
less, mosaic mtDNA depletion was evident in ﬁbroblast cultures
from only the most severely affected children, all of whom had
died before the age of 16 months. Patient D had two mutations,
R232G and T251I, in the exonuclease domain, the latter being
in cis with the P587L linker mutation. The P587L mutation
usually co-segregates with T251I, but has occurred with 251T
in a patient with a relatively mild phenotype (28). While this
suggests that P587L is mildly pathogenic, T251I may exacer-
bate its effect. Patient M was homozygous for the L304R exo-
nuclease mutation and had a relatively mild phenotype, but
neither liver nor ﬁbroblasts were available for study. In contrast
to the patients with two catalytic mutations, no patient who only
had missense linker mutations was dead by 16 months or had
mosaic cellular or tissue mtDNA depletion.
Figure 3. Continued.
2502 Human Molecular Genetics, 2008, Vol. 17, No. 16Depletion of mtDNA was present in liver in all cases where
it was available for measurement, but was much less consist-
ent than in muscle. All patients with hepatic mtDNA depletion
had at least one catalytic mutation, whereas patients with
purely linker mutations had little in the way of liver features.
These were usually missense mutations, but one patient had a
nonsense mutation in the polymerase domain resulting in
mono-allelic expression (21,24). We found cellular mtDNA
depletion only in individuals with clear tissue depletion
(Table 2). The severity of the depletion was commensurate
with the severity of the defect in replication that we have
seen, and this is supported by the published literature (29).
These genotype–phenotype correlations may not have been
seen in some previous studies because the diagnosis of
mtDNA depletion syndrome is frequently imprecise. This is
for both technical reasons (25) and because of the lack of
established age-adjusted normal ranges, and may explain
some of the inconsistencies in the published literature.
However, age-related changes in mtDNA content are undoubt-
edly also a feature of mtDNA depletion (18,25,30,31). Fur-
thermore, it is clear that the effect of speciﬁc mutations may
be modulated by other missense mutations in cis (32,33).
An important aspect of this study is the use of PicoGreen to
visualize mtDNA packaged into nucleoids. While PicoGreen is
less sensitive that antiDNA antibodies and does not detect
nucleoids containing the lowest levels of mtDNA, it can be
used more quantitatively than antiDNA antibodies, being sensi-
tive to the nucleoid DNA content (23). With this method, it
could be shown that both the number of nucleoids and the
average mtDNA content in individual cells declined with time
in ﬁbroblast cultures from the patients with the mosaic cellular
depletionphenotype(Fig.2).Duringthisdecline,thedistribution
of nucleoid intensities remained similar within the range where
the PicoGreen signal is quantitative (23). This might indicate
that the balance between nucleoid fusion and division depends
more on the mtDNA content of the nucleoid than the number of
nucleoids in the cell. It may also explain our observation that
occasional mitochondria within TFAM depleted cells retained
Mitotracker labelling (Supplementary Material, Fig. S2).
Occasional nucleoids of relatively normal mtDNA content in
cells that are profoundly depleted of mtDNA may underlie the
co-localization of Mitotracker and residual TFAM signal.
Like many replicases, POLG1 has a 30 to 50 nuclease
activity that is used to excise incorrectly paired bases.
Mutations in this domain have been seen in both childhood
and adult onset POLG1 disease. In the mutator mouse
model, POLG1 with deﬁcient exonuclease activity impairs
both polymerase ﬁdelity and shortens lifespan (34,–36). By
analogy with other DNA polymerases, the enzyme probably
alternates between polymerizing and editing modes, as deter-
mined by competition between the two active sites for the 30
primer end of the DNA (37). Once the correct base has been
incorporated, the enzyme moves forward 1 bp further, ready
for the next precursor nucleotide to enter. Patient B, who is
a compound heterozygote with one mutation in the polymerase
and one in the exonuclease domain, has a severe cellular and
clinical phenotype, comparable with patients A, C and D, who
either have two polymerase (patients A and C) or two exonu-
clease mutations (patient D). The apparent lack of comple-
mentation between the POLG1 mutations in patient B
supports the molecular model, by suggesting that normal
mtDNA replication requires both polymerase and exonuclease
activity within the same alpha subunit.
Previous studies of patients with POLG1 mutations have
found limited correlation between phenotype and genotype
(38–40). Horvath et al. (38) reported that patients with
Alpers disease generally had at least one catalytic mutation,
most commonly in the polymerase domain, and that patients
whose mutations both lay in the linker domain presented
later. Bindoff and coworkers (27) studied 26 individuals
with two common linker mutations, A467T and W748S. The
A467T mutation inﬂuences the interaction of POLG1 with
POLG2 and the W748S mutation reduces both processivity
and DNA binding. These authors found major differences in
survival depending on genotype, with compound heterozy-
gotes having a signiﬁcantly shorter survival time than patients
homozygous either for the A467T or W748S mutations. As the
active form of POLG is known to be a compound heterotrimer
containing one alpha and two beta subunits, this suggests a
quaternary interaction between catalytic subunits in different
heterotrimers. While our data set is much too small to draw
parallel inferences, we saw nothing to suggest quaternary
interactions between polymerase domains. Patient C, who
was homozygous for the R1096C mutation, had a comparable
cellular and clinical phenotype to patient A, who was a com-
pound heterozygote for this mutation and T914P.
Sixof theotherPOLG1mutations weidentiﬁed have notbeen
reported previously. These comprise one nonsense mutation
(R374X), one 10 amino acid deletion (W347_L356del), three
simple missense mutations (H277L, R417T, H569Q) and one
allele with two missense mutations (P587L;P589L). While
P589L is novel, it is in cis with P587L which has been reported
as a recessive mutation. H277L, R417T and H569Q are all
within nine amino acids of previously reported recessive
Table 2. Summary of mutation by location and phenotypic severity: Colour represents severity running from dark orange (most severe) to white (least severe)
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mammalianspecies.Inaddition,R417Tmayleadtoaberrantspli-
cing as the last nucleotide of exon 6 is mutated (1250G.C).
Wanrooij et al. (41) used two dimensional DNA analysis to
show that cells, over-expressing POLG1 or TWINKLE con-
taining catalytic defects, have both cellular depletion of
mtDNA and replisome stalling. In some of their cell lines,
the mtDNA depletion was apparent as reduced numbers of
nucleoids. We have previously shown that intra-mitochondrial
nucleotide imbalance occurs in cells from patients with
mutations in TK2, dGK, TWINKLE and, potentially, TP
(24). Nucleotide imbalance is another potential cause of repli-
some pausing and depletion, and cells that are deﬁcient in
dGK may also have mosaic mtDNA depletion (25,42). Repli-
some pausing may thus underlie mtDNA depletion due to
either POLG1 mutations (41) or to nucleotide imbalances
(43). The mosaic cellular depletion that we have demonstrated
may thus be a manifestation of severe replication stalling. As
in the model proposed by Wanrooij et al., we found that each
of the ﬁbroblast cultures from patients A–D (that had the most
severe cellular depletion) had at least two POLG1 mutations
lying in catalytic domains. The depletion in the patient cells
was less pronounced than in the in vitro study, however, the
progressive depletion observed with successive passages of
patient cells may partly recapitulate the depletion observed
on induction of the mutant POLG1 in the experimental study.
The clinical ﬁndings in this group of patients are similar to
those found in previous studies of POLG1 mutations in Alpers
disease. The prominence of epilepsy has been highlighted
before, as well as the variability in pointers to mitochondrial
disease. Movement disorders appear to be very much more
common than in maternally inherited mtDNA disease,
especially if this feature is broadened to include epilepsia par-
tialis continua. Thus, epilepsia partialis continua and move-
ment disorders may provide an important pointer to POLG1
mutations. In one case, fatal deterioration followed valproate
therapy and others have reported a clear improvement on stop-
ping therapy with this anticonvulsant. However, several other
patients, with a generally milder phenotype, have been treated
with this drug for short periods without apparent problem. The
relationship between the hepatic encephalopathy associated
with valproate therapy and pre-existing POLG mutations
(carrier frequency ,1 in 150) is worthy of further study.
Among a group of patients with POLG1 mutations, we have
identiﬁed and characterized mosaic cellular depletion of mito-
chondrial DNA in four patients, each with two mutations affect-
ing catalytic domains. These mutations appear to have severe
consequences, both for the clinical phenotype and the mtDNA
content of affected tissues. Patients with demonstrable tissue
mtDNA depletion always had at least one catalytic domain or
nonsense mutation. Our ﬁndings add general support to the
current model of the role of POLG1 in the replisome.
MATERIALS AND METHODS
Patients
Patients were referred to our diagnostic service with a variety
of clinical presentations. In two cases (we received ﬁbroblasts,
the patients having been diagnosed at other centres [patient D
(37) and J (21,24)]. Alpers was diagnosed on the basis of the
referring clinician’s information, some of which was collected
retrospectively (Table 1). Case histories for patients A–C are
in the Supplementary Material.
Materials
All chemicals were from Sigma-Aldrich Ltd or Biomol Inter-
national. Antibodies to TFAM were raised in our own lab,
anti-DNA was from ProGen Biotechnick GmbH. Anti-BrdU
antibody was from Roche. Alexaﬂuor secondary antibodies,
mouse anti-COXI, PicoGreen and Mitotracker Red were
from Invitrogen Corp.
Cell culture
Fibroblast cultures were all free of mycoplasma by routine
screening and were cultured in Dulbeco’s modiﬁed essential
medium, with 4.5 g/l glucose supplemented with 10% fetal
bovine serum (PCL International UK Ltd), 20 mM pyruvate,
2m M glutamate and 100 units/ml penicillin/streptomycin and
50 mM uridine.
DNA extraction
Approximately 4   10
6 cells were re-suspended in 2 ml of
DNA extraction buffer and incubated at 508C for 1–3h.
The DNA was then precipitated with the addition of an
equal volume of isopropanol at room temperature and the
DNA pellet washed three times in 70% ethanol before air
drying, and re-suspension Tris–EDTA buffer, pH 7.4. In
some experiments DNA was extracted by using a QIAamp
DNA mini kit, as per manufacturer’s instructions.
Cytochemical staining
Cells were grown overnight in six well plates. MtDNA stain-
ing in live cells was achieved by diluting stock PicoGreen sol-
ution at 3 ml/ml (1–3 h). The cells were rinsed three times in
pre-warmed PBS and mounted with phenol red free DMEM
supplemented with 4.5 g/l glucose and 25 mM HEPES buffer,
and visualized using an epiﬂuorescent microscope. Cells
were co-stained after PicoGreen labelling with TMRM by
incubation for 30 min in medium containing 30 nM TMRM
at 378C.
For immunocytochemical staining, cells were ﬁxed for
20 min with 4% paraformaldehyde in PBS, and permeabilized
with 0.5% triton-X in PBS for 15 min. The cells were
then incubated with primary antibodies for 1 h. Antibody
dilutions were anti-TFAM antibody at 1:60, anti-COX
subunit I at 10 mg/ml, anti-DNA 1:10. After incubation,
the cells were rinsed in PBS and primary antibodies were
visualized using ﬂuorescent-tagged secondary antibodies.
Antibody dilutions were: Anti-rabbit FITC (1:60), anti-mouse
FITC (1:75), anti-rabbit TRITC (1:60). After incubation, the
cells were counterstained with 0.5 mg/ml DAPI, rinsed in
PBS X3, and mounted using Hydromount. For Mitotracker
co-labelling cells were incubating with 100 nM Mitotracker
for 30 min, with a further 25 min in dye-free medium,
before ﬁxation.
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DNA (44), cells were incubated for 3–7 h in DMEM sup-
plemented with 15 mM bromodeoxyuridine (BrdU), and ﬁxed
in glycine ﬁx (–208C) for 40 min. The cells were gently
re-hydrated and the cells were incubated with anti-BrdU
with nucleases, for 45 min at 378C. The primary was visual-
ized with an anti-mouse secondary, and the cells mounted.
Histochemical staining of cytochrome c oxidase
and SDH activity
Cells to be stained for cytochrome c oxidase (COX) activity
were grown on sterile glass cover slips overnight. Cells were
rinsed with ice-cold PBS, and once with 50% PBS in water,
and all traces of ﬂuid removed. Cells were air-dried and
then incubated at 378C with freshly prepared modiﬁed staining
buffer, consisting of 10% sucrose, 100 mM of fully reduced
bovine cytochrome c, 8 units catalase, 1 mg/ml DAB and
0.25% DMSO, 10% sucrose in 20 mM sodium phosphate
buffer (pH 7). After incubations, a brown deposit of insoluble
DAB polymer representing COX activity is generated by
single electron reduction of DAB monomer. The staining
buffer was removed, and the cells rinsed once with 20 mM
phosphate buffer, followed by post ﬁxation in 4% paraformal-
dehyde, and mounted in Hydromount. An azide treated nega-
tive control was included with each experiment.
SDH activity was measured as described (45), with modiﬁ-
cations. The cells were air-dried as above, and incubated in
0.1M phosphate buffer (pH 7) containing 1.5 mM nitroblue tet-
razolium, 130 mM sodium succinate, 0.2 mM phenazine meth-
osulfate and 1.0 mM sodium azide, for 1–2 h at 378C.
Microscopy and digital image analysis. Image capture was
done using SimplePCI, and ﬁgures were constructed with
Photoshop. Quantitative image analysis was performed on
unprocessed images using ImageJ (http://rsb.info.nih.gov/ij/
download.html), and ﬂuorescent intensities calculated using
the sum of pixel grey scale values, corrected for mean local
cellular background.
Real-time quantitative PCR. Estimation of relative mtDNA to
nDNA levels were performed as described previously (23),
except the nuclear probe was labelled with Vic at the 50 end
and the ampliﬁcation reactions were done simultaneously
using a GeneAmp 7700 sequence detection system.
Statistical analysis
t-tests were carried out using the SPSS package version 15.0.
Analysis of the POLG gene
The entire coding region and ﬂanking intronic regions (at least
10 nucleotides) of POLG were ampliﬁed by PCR from
genomic DNA and sequenced by ﬂuorescent dideoxy sequen-
cing (Applied Biosystems BigDye Terminator v1.1 kit) and
capillary electrophoresis (Applied Biosystems 3730) (primers
and conditions available on request). Results were compared
with GenBank reference sequences NT_033276.4 and
NM_002693.1. Nucleotide numbering was assigned using
the A of the ATG translation initiation codon as nucleotide
1. The POLG p.A467T, p.W748S and p.G848S mutations
were also analysed by PCR and restriction enzyme digest
(primers, restriction enzymes and conditions available on
request).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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